
ASCO: AstraZeneca, Daiichi flex Enhertu's muscles in first-line breast cancer as they drop new phase 3 gastric cancer ...
More than five years after an initial FDA approval as a third-line treatment for HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu looks poised to reach newly diagnosed patients, with efficacy data that live up …